Details of the Drug
General Information of Drug (ID: DM97MGE)
| Drug Name |
N-(2-hydroxyethyl)linoleoylamide
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Linoleamide MEA; Linoleoyl ethanolamide; Linoleic ethanolamide; n-linoleoylethanolamine; N-(2-Hydroxyethyl)linoleamide; Anandamide (18:2, n-6); Linoleoyl monoethanolamide; UNII-889DYX0816; N-(2-hydroxyethyl)linoleoylamide; Linoleylethanolamide; 68171-52-8; Monoethanolamine linoleic acid amide; EINECS 269-029-6; N-(9Z,12Z-octadecadienoyl)-ethanolamine; CHEMBL149859; N-(2-Hydroxyethyl)-linoleamide; C20H37NO2; CHEBI:64032; 889DYX0816; (9Z,12Z)-N-(2-Hydroxyethyl)octadeca-9,12-dien-1-amide
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 323.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 5.6 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 16 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


